Skip to content
10-Q

Quarterly Report

IMMIX BIOPHARMA, INC. IMMX

0001493152-26-021764

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 54.41M sh
Shares Diluted Q1 2026 · Mar 31, 2026 55.37M sh
Shares Diluted Q1 2026 · Mar 31, 2025 29.7M sh
Capex Q1 2026 · Mar 31, 2026 $32.49K
Capex Q1 2026 · Mar 31, 2025 $67.71K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$9.83M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$1.69M
Short Term Investments Q1 2026 · Mar 31, 2026 $11.33M
Short Term Investments Q1 2026 · Dec 31, 2025 $6.48M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $79.25M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $93.93M
Stockholders Equity Q1 2026 · Mar 31, 2026 $84.36M
Stockholders Equity Q1 2026 · Dec 31, 2025 $93.8M
Stockholders Equity Q1 2026 · Mar 31, 2025 $9.59M
Stockholders Equity Q1 2026 · Dec 31, 2024 $13.25M
Current Liabilities Q1 2026 · Mar 31, 2026 $10.54M
Current Liabilities Q1 2026 · Dec 31, 2025 $10.11M
Total Liabilities Q1 2026 · Mar 31, 2026 $11.45M
Total Liabilities Q1 2026 · Dec 31, 2025 $11.04M
Current Assets Q1 2026 · Mar 31, 2026 $92.27M
Current Assets Q1 2026 · Dec 31, 2025 $101.24M
Total Assets Q1 2026 · Mar 31, 2026 $95.82M
Total Assets Q1 2026 · Dec 31, 2025 $104.84M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.18
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.15
Eps Basic Q1 2026 · Mar 31, 2026 −$0.18
Eps Basic Q1 2026 · Mar 31, 2025 −$0.15
Sga Expense Q1 2026 · Mar 31, 2026 $4.82M
Sga Expense Q1 2026 · Mar 31, 2025 $2.71M
Rd Expense Q1 2026 · Mar 31, 2026 $5.98M
Rd Expense Q1 2026 · Mar 31, 2025 $1.98M
Net Income Q1 2026 · Mar 31, 2026 −$10.09M
Net Income Q1 2026 · Dec 31, 2025 −$29.4M
Net Income Q1 2026 · Mar 31, 2025 −$4.54M
Operating Income Q1 2026 · Mar 31, 2026 −$10.8M
Operating Income Q1 2026 · Mar 31, 2025 −$4.68M
Revenue Q1 2026 · Dec 8, 2022 $20M